ASPIRE-Hemophilia Regional Eligibility

Applicants must meet the following requirements. Proposals not meeting the requirements listed below will be rejected.

Academic Eligibility

To be eligible for a Regional Haemophilia ASPIRE Awards, applicants must have a professional degree (MD, PhD, PharmD or equivalent). Investigators must be qualified to carry out the proposed investigation. Assessments of investigator qualification will be made on the basis of their commitment to research in this area, a dedicated faculty assignment and previous research and publication experience. They also need to reside in one of the following countries: Australia, Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, Kyrgyzstan, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Mongolia, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK, Ukraine

Note: Current external review panel members are not eligible to apply, either as applicant or co-applicant. Serving as a mentor, however, to an applicant is permitted

Research Requirements

Applicants / Investigators are expected to:
  • Design studies and generate data to address at least one of the Areas of Research Focus (see FAQs)
  • Provide a Publication Plan describing submission of abstracts to (a) congress(es) or submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines
  • Complete the study within 12 months from the time that the grant is awarded

Criteria for Selection - Independent, External Review Committee

The ASPIRE Research Award proposals will be reviewed by an independent, external review committee comprising experts in haemophilia. Grants will be awarded based upon:

  • Scientific merit of the research proposal
  • Qualifications of the applicant
  • Relevance of proposed research to the programme's mission
  • Evidence of the applicant's commitment to an academic research career
  • Evidence of a suitable research environment
  • Special consideration will be given to early-career (e.g., fellows, junior faculty) applicants.
Note: A preliminary review of submissions will be completed by Pfizer in order to ensure proposals are within the scope of research areas, and that there are no concerns with the proposed work from a patient safety or intellectual property perspective. If concerns are identified, the proposal may be rejected prior to evaluation by the external review committee.

Other Funding

No other government, non-governmental, or industry-sponsored projects may cover the same scope of work as the grant application to the ASPIRE Research Awards Programme. However, an ASPIRE Research Award may be related to other funding from foundations or government agencies, as long as there is no direct overlap. In the application, it is the responsibility of the applicant to justify the novelty of the proposal and provide evidence that the application does not overlap with any current or pending funding.

Once awarded, an ASPIRE Research Award cannot be amended upwards with additional funding support from Pfizer (via the standard IIR process or separate competitive grant programme), nor can additional drug support above and beyond what is sufficient to complete the original study as reviewed and approved by the external review committee be provided. If supplemental funding is required, it must be secured from sources outside of Pfizer. Similarly, an ongoing Pfizer supported standard IIR cannot apply for supplemental funding via a Pfizer-supported competitive grant programme.

ASPIRE Research Awards cannot be provided to studies that are already in progress.

Questions

See the Frequently Asked Questions (FAQ) for help.

You may also e-mail questions to questions.europeaspire@pfizer.com

 



 

PP-GIP-EUR-1106
Date of preparation: November 2017